Thomson Reuters Acquires GeneGo to Provide Pathway Analysis 'Complement' for Life Science Portfolio

According to the company, GeneGo's tools and expertise complement its life sciences portfolio and will provide its clients with a better understanding of underlying disease mechanisms, as well as potential therapies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.